Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride may cause depression, suicidal thoughts, and sexual side effects.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study found that finasteride use was significantly associated with reports of obstructive sleep apnea and insomnia compared to other drugs in the FAERS database.

This review discusses the challenges in addressing female sexual dysfunction, focusing on the complexities of female sexual response, levels of dysfunction, clinical identification, and existing treatments, but presents no new clinical findings.

The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.

This study concluded that transurethral seminal vesiculoscopy combined with finasteride is a safe and effective treatment for recurrent hemospermia in the observed patients.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

The study observed that finasteride reduced fertility in male Sprague-Dawley rats by impairing the formation of copulatory plugs, an effect considered specific to rats and not applicable to species without this reproductive feature.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

In this case report, a 31-year-old man developed erosive pustular dermatosis of the scalp after hair transplant surgery, highlighting potential surgical trauma as a trigger for this condition in younger patients.

This study found that inhibiting 5αR1 with dutasteride leads to peripheral insulin resistance and increased body fat in men, which may have implications for its use in treating benign prostatic hyperplasia.

This review highlights potential negative impacts of certain medications on male fertility, such as hormonal disruption and germ cell toxicity, emphasizing the importance of clinicians being aware of these effects to advise on safer alternatives.

This report describes two cases of stroke associated with finasteride use for male-pattern hair loss, suggesting a potential link to thrombosis due to increased estrone and estradiol levels.

This retrospective analysis of male patients undergoing hair restoration surgery for androgenetic alopecia found that postoperative edema was the most common complication, occurring in 42.47% of cases.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

Patients follow treatment well, but many change medicines; good information helps compliance.

This review discusses finasteride, developed by Merck, as a treatment for benign prostatic hyperplasia and notes its potential effectiveness for male androgenetic alopecia, but reports no new clinical results.

This study in Bangladesh reports that 81% of patients with refractory idiopathic hematospermia showed remission after three months of finasteride treatment, significantly higher than the 27% remission rate in the placebo group, with results sustained for some time after stopping the medication.

Dutasteride helps reduce male pattern hair loss, but may cause side effects like altered libido and erectile dysfunction.

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.

This review of legal cases found that 5α-reductase inhibitors, alleged to cause sexual, mental, and physical side effects, have led to numerous lawsuits with increasing litigation expected in the future.

This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.

This case study concluded that weight loss is the initial recommended approach for treating secondary hypogonadism, as shown by improvements in testosterone levels and symptoms in an obese 37-year-old patient.